Erratum to "The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial" [J. Neuroimmunol. 201-202(2008)80-84] (DOI:10.1016/j.jneuroim.2008.05.031);The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 80-84

  Aban, Inmaculada B ^a   Wolfe, Gil I ^b   Cutter, Gary R ^a   Kaminski, Henry J ^c   Jaretzki III, Alfred ^d   Minisman, Greg ^a   Conwit, Robin ^e   Newsom Davis, John ^f   Advisory Committee, MGTX ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NONE

Author keywords

Myasthenia gravis; Regulatory approval; Thymectomy

Indexed keywords

PREDNISONE;

ARTICLE; GOVERNMENT REGULATION; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MEDICAL EDUCATION; MYASTHENIA GRAVIS; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL TECHNIQUE; THYMECTOMY; TREATMENT OUTCOME;

EID: 51649110864     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.07.002     Document Type: Erratum

References (12)

1. Burris S. Regulatory innovation in the governance of human subjects research: a cautionary tale and some modest proposals. Regul. Govern. 2 (2008) 65-84
2. Chiu H.-C., Vincent A., Nemsom-Davis J., Hsieh K.-H., and Hung T.-p. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 37 (1987) 1854-1857
3. Collins J.F., Garg R., Teo K.K., Williford W.O., Howell C.L., and on behalf of the DIG Investigators. The role of the data coordinating center in the IRB review and approval process: the DIG trial experience. Control. Clin. Trials 24 (2003) 306S-315S
4. Compston D.A.S., Vincent A., Newsom-Davis J., and Batchelor J.R. Clinical, pathological, HLA antigen, and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103 (1980) 579-601
5. Duley L., Antman K., Arena J., Avezum A., Blumenthal M., Bosch J., Chrolavicius S., Li T., Ounpuu S., Perez A.C., Sleight P., Svard R., Temple R., Tsouderous Y., Yunis C., and Yusuf S. Specific barriers to the conduct of randomized trials. Clin. Trials 5 (2008) 40-48
6. Heckmann J.M., Owen E.P., and Little F. Myasthenia gravis in South Africans: racial differences in clinical manifestations. Neuromuscul. Disord. 17 (2007) 929-934
7. McNay L.A., Tavel J.A., Oseekey K., McDermott C.M., Mollerup D., Bebchuk J.D., and ESPRIT Group. Regulatory approvals in a large multinational clinical trial: the ESPRIT experience. Control. Clin. Trials 23 (2002) 59-66
8. Newsom-Davis J., Cutter G., Wolfe G.I., Kaminski H.J., Jaretzki III A., Minisman G., Aban I., and Conwit R. Status of the thymectomy trial for non-thymomatous myasthenia gravis patients receiving prednisone. Ann. N.Y. Acad. Sci. 1132 (2008) 344-347
9. Phillips L.H. The epidemiology of myasthenia gravis. Ann. N.Y. Acad. Sci. 998 (2003) 407-412
10. Phillips L., Torner J., Anderson M., and Cox G. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42 (1992) 1888-1893
11. Wolfe G., Kaminski H.J., Jaretzki A., Swan A., and Newsom-Davis J. Thymectomy trial in non-thymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann. N.Y. Acad. Sci. 998 (2003) 473-480
12. Wong V., Hawkins B.R., and Yu Y.L. Myasthenia gravis in Hong Kong Chinese. Acta Neurol. Scand. 86 (1992) 68-72